Using model proteins to quantify the effects of pathogenic mutations in Ig-like proteins

被引:30
作者
Randles, Lucy G. [1 ]
Lappalainen, Ilkka [1 ]
Fowler, Susan B. [1 ]
Moore, Benjamin [1 ]
Hamill, Stefan J. [1 ]
Clarke, Jane [1 ]
机构
[1] Univ Cambridge, Dept Chem, MRC, Ctr Prot Engn, Cambridge CB2 1EW, England
关键词
D O I
10.1074/jbc.M603593200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It has proved impossible to purify some proteins implicated in disease in sufficient quantities to allow a biophysical characterization of the effect of pathogenic mutations. To overcome this problem we have analyzed 37 different disease-causing mutations located in the L1 and IL2R gamma proteins in well characterized related model proteins in which mutations that are identical or equivalent to pathogenic mutations were introduced. We show that data from these models are consistent and that changes in stability observed can be correlated to severity of disease, to correct trafficking within the cell and to in vitro ligand binding studies. Interestingly, we find that any mutations that cause a loss of stability of more than 2 kcal/mol are severely debilitating, even though some model proteins with these mutations can be easily expressed and analyzed. Furthermore we show that the severity of mutation can be predicted by a Delta Delta G(evolution) scale, a measure of conservation. Our results demonstrate that model proteins can be used to analyze disease-causing mutations when wild-type proteins are not stable enough to carry mutations for biophysical analysis.
引用
收藏
页码:24216 / 24226
页数:11
相关论文
共 57 条
[1]  
Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkp985, 10.1093/nar/gkr1065, 10.1093/nar/gkh121]
[2]   Outline structure of the human L1 cell adhesion molecule and the sites where mutations cause neurological disorders [J].
Bateman, A ;
Jouet, M ;
MacFarlane, J ;
Du, JS ;
Kenwrick, S ;
Chothia, C .
EMBO JOURNAL, 1996, 15 (22) :6050-6059
[3]   Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy [J].
Bullock, AN ;
Henckel, J ;
Fersht, AR .
ONCOGENE, 2000, 19 (10) :1245-1256
[4]   Rescuing the function of mutant p53 [J].
Bullock, AN ;
Fersht, A .
NATURE REVIEWS CANCER, 2001, 1 (01) :68-76
[5]   Predicting the functional consequences of non-synonymous single nucleotide polymorphisms: Structure-based assessment of amino acid variation [J].
Chasman, D ;
Adams, RM .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 307 (02) :683-706
[6]   ENGINEERED DISULFIDE BONDS AS PROBES OF THE FOLDING PATHWAY OF BARNASE - INCREASING THE STABILITY OF PROTEINS AGAINST THE RATE OF DENATURATION [J].
CLARKE, J ;
FERSHT, AR .
BIOCHEMISTRY, 1993, 32 (16) :4322-4329
[7]   Folding studies of immunoglobulin-like β-sandwich proteins suggest that they share a common folding pathway [J].
Clarke, J ;
Cota, E ;
Fowler, SB ;
Hamill, SJ .
STRUCTURE WITH FOLDING & DESIGN, 1999, 7 (09) :1145-1153
[8]   Folding and stability of a fibronectin type III domain of human tenascin [J].
Clarke, J ;
Hamill, SJ ;
Johnson, CM .
JOURNAL OF MOLECULAR BIOLOGY, 1997, 270 (05) :771-778
[9]  
Cota E, 2000, PROTEIN SCI, V9, P112
[10]   The folding nucleus of a fibronectin type III domain is composed of core residues of the immunoglobulin-like fold [J].
Cota, E ;
Steward, A ;
Fowler, SB ;
Clarke, J .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 305 (05) :1185-1194